TG Therapeutics Inc — Cash Flow (NASDAQ:TGTX) | MetaTrader

Open full chart

Financials

Overview Rapor Statistics

Quarterly Annual

Cash from operating activities -214.51 M-295.63 M-176.17 M-31.41 M-40.52 M-24.77 M -24.77 M Cash from investing activities -24.51 M-332 K-20.01 M-50.65 M-1.04 M13.8 M 13.8 M Cash from financing activities 679.83 M41.42 M-391 K72.7 M128.53 M-89.73 M -89.73 M Free cash flow -214.86 M-296.04 M-176.18 M-31.41 M-40.56 M-24.99 M -24.99 M

Haberler

TG Therapeutics: Briumvi Performance Aiding Upside, Buybacks Limiting Downside (TGTX)

TG Therapeutics, Blue Owl’dan 750 milyon dolarlık kredi aldı

BRIUMVI yüksek aktif multipl skleroz hastalarında etkinlik gösterdi

BRIUMVI shows efficacy in highly active multiple sclerosis patients

TG Therapeutics nöroloji toplantısında BRIUMVI verilerini sunacak

TG Therapeutics to present BRIUMVI data at neurology meeting

TGTX Q4 Earnings Lag Estimates, Briumvi Sales Drive Top Line

TG Therapeutics (TGTX) Misses Q4 Earnings Estimates

TG kazancı $0,23 ile beklentilere göre daha kötü, kâr ise beklentilere göre yüksek

TG earnings missed by $0.23, revenue topped estimates

Geron (GERN) Reports Q4 Loss, Misses Revenue Estimates

TG Therapeutics faces earnings test as Briumvi growth accelerates